Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on May 22, 2015. The filing documents events occurring at the Company's Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a dividend declaration:
- Dividend Declaration: A quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock.
- Payment Date: August 1, 2015.
- Record Date: July 17, 2015.
Material Changes and Corporate Actions
The following material events were reported:
- Equity Incentive Plan: Stockholders approved the 2015 Equity Incentive Plan.
- Director Elections: Three Class 3 directors were elected to serve until the 2018 annual meeting:
- Paul McBarron
- Dr. Nicholas Bacopoulos
- Dr. Christopher Henney
- Auditor Ratification: McGladrey LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2015.
- Executive Compensation: An advisory vote approved the compensation of named executive officers.
Voting Results Summary
| Proposal | Votes For | Votes Against/Withheld | Broker Non-Votes | Outcome |
|---|---|---|---|---|
| Election of Directors (All 3 nominees) | ~9.2M each | ~430k-460k each | 11,958,650 | Approved |
| Ratification of Auditor | 20,354,331 | 912,351 (Against) | 0 | Ratified |
| 2015 Equity Incentive Plan | 8,988,101 | 619,445 (Against) | 11,958,650 | Approved |
| Executive Compensation (Say-on-Pay) | 8,907,492 | 688,553 (Against) | 11,958,650 | Approved |
Outlook, Risks, and Management Commentary
Regarding the dividend declaration, the Board noted that while they will analyze the advisability of declaring dividends in future quarters, there is no assurance that future quarterly dividends will be declared. The decision was based on financial analysis and the determination of a surplus.
Investor Verification Checklist
- Verify the correct registrant name is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Confirm the terms of the 2015 Equity Incentive Plan in the attached Exhibit 10.1.
- Monitor the Company's financial position to assess the likelihood of future preferred stock dividends.
- Review the definitive proxy statement (Schedule 14A filed April 7, 2015) for detailed compensation data.